ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company specializing in developing therapies to combat resistance mechanisms in cancer, with ongoing clinical trials for several investigational drug candidates.
Company Overview
ORIC Pharmaceuticals is a biotechnology company that develops therapies targeting resistance mechanisms in cancer. The company has a pipeline of novel agents designed to tackle multiple types of resistance, including innate resistance, acquired resistance, and bypass resistance. Headquartered in South San Francisco, CA, ORIC also has offices in San Diego, CA.
Therapeutic Areas of Focus
ORIC Pharmaceuticals concentrates on three main areas of cancer resistance: innate resistance, acquired resistance, and bypass resistance. By developing agents that specifically target these resistance mechanisms, ORIC aims to enhance the efficacy of cancer treatments and improve patient outcomes.
Pipeline and Investigational Drugs
The company has a robust pipeline of investigational drugs targeting various resistance mechanisms in cancer. Key agents in clinical trials include ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2 cancers, and ORIC-944 for prostate cancer. Each of these drug candidates is currently enrolling participants in phase 1 studies.
Clinical Trials
ORIC Pharmaceuticals is actively conducting clinical trials to evaluate the efficacy and safety of its investigational drug candidates. Current trials include studies for ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer. These phase 1 trials are essential steps in the development and potential approval of these novel therapies.
Locations
ORIC Pharmaceuticals is headquartered in South San Francisco, CA, a prime location for biotechnology innovation. The company also maintains additional offices in San Diego, CA, further extending its presence in key biotech hubs.